Money · Federal contracts

DUKE UNIVERSITY

$3,646.89 in contract dollars, fiscal year 2027Confirmed from the official record
Unique Entity ID (UEI)
TP7EK8DZV6N5
Parent company
DUKE UNIVERSITY (this vendor is its own parent)
Registered address
DURHAM, NC, district NC-04
Other names on record
DUKE UNIVERSITY; DUKE UNIVERSITY HEALTH SYSTEM INC.; DUKE UNIVERSITY HOSPITAL; DUKE UNIVERSITY MEDICAL CENTER; DUKE UNIVERSITY PRESS; DUKE UNIVERSITY, MEDICAL SCHOOL; DUKE UNIVERSITY, TRINITY COLLEGE OF ARTS & SC; PRIVATE DIAGNOSTIC CLINIC PLLC; UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL

Dollars are contract obligations in the fiscal year, as USAspending adds them up from each award's transactions. A contract's full value can be larger and run over several years. A figure below zero is money taken back from contracts signed earlier.

Source: USAspending.gov, the Treasury’s public record of federal spending. Our copy was saved November 19, 2026.

The largest vendors

Which agencies pay this vendor, and where the work is done

Fiscal year 2027: $3,646.89

Contract dollars by awarding agency, Fiscal year 2027
AgencyContract dollars
National Aeronautics and Space Administration$41,666.67
Department of Veterans Affairs-$14,608
Department of Health and Human Services-$23,411.78
Contract dollars by House district, Fiscal year 2027
District where the work is doneContract dollars
NC-04Valerie P. Foushee$3,646.89

Fiscal year 2026: $58,203,851.54

Contract dollars by awarding agency, Fiscal year 2026
AgencyContract dollars
Department of Health and Human Services$55,423,368.48
Department of Defense$1,524,952.62
Department of Veterans Affairs$780,387
National Aeronautics and Space Administration$461,172
Department of Agriculture$30,012
Department of the Interior-$16,040.56
Contract dollars by House district, Fiscal year 2026
District where the work is doneContract dollars
NC-04Valerie P. Foushee$56,928,541.54
MD-08Jamie Raskin$1,256,810
NC-09Richard Hudson$18,500
CA-19Jimmy Panetta$0
MD-04Glenn Ivey$0

Largest awards

The largest contract awards with activity from October 1, 2025 to September 30, 2027, by each award's total amount over its whole life. 1 rows of the answer belong to related companies and are left out.

Largest contract awards, by each award's total over its life
AwardAgencyWhere the work is doneAward totalStart
75N93019C00053COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY COREDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$77,629,981.68Ends September 30, 2029
75N93019C00050THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUSTDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$67,973,442.64Ends July 28, 2027
HHSN272201700061CIGF::OT::IGF EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL)Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$35,846,627.14Ends September 29, 2024
75N93019C00054COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) - COMPONENT C: CLINICAL CORE (AWARDED POP: SEPTEMBER 16, 2019 - SEPTEMBER 15, 2020)Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$35,619,447.24Ends December 31, 2030
75R60220C00008NATIONAL CORD BLOOD INVENTORYDepartment of Health and Human ServicesHealth Resources and Services AdministrationDURHAM, NC-04$31,016,848Ends September 3, 2036
75N93019C00015IGF::OT::IGF NIAID VIROLOGY QUALITY ASSURANCE (VQA)Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$24,039,431.64Ends June 20, 2026
75N93022C00055"ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES"Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$18,032,120.76Ends May 31, 2028
HHSN272201800004CIGF::OT::IGF NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENTDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$17,977,569.61Ends March 29, 2025
75N93024F00001EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL)Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$12,075,641Ends September 29, 2027
75N93021C00010IMMUNOLOGY QUALITY ASSESSMENT (IQA) PROGRAMDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$10,850,735.53Ends September 29, 2027
75N94023F00004BPCA INNOVATIVE TRIAL DESIGNS AND ASSAY DEVELOPMENTS IN PEDIATRIC THERAPEUTICSDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$8,783,682Ends September 27, 2027
75N93022C00053ADJUVANT COMPARISON AND CHARACTERIZATIONDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$8,457,032Ends April 30, 2028
75N94026F00002NICHD: R&D: BESPOKE GENE THERAPY CONSORTIUM (BGTC) - SUPPORT FOR NIH-SPONSORED CLINICAL TRIALS: NON-SEVERABLEDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$8,301,883Ends September 27, 2030
75N94019F00126TO PROVIDE A PLATFORM FOR THE INCLUSION OF PATIENTS WITH DOWN SYNDROME INTO THE PHARMACOLOGY-BASED CLINICAL TRIALS. THE GOALS ARE TO RECRUIT THIS PATIENT POPULATION INTO THE PEDIATRIC TRIALS NETWORK OPPORTUNISTIC STUDY MODEL AND TO DEVELOP A TRAININGDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$6,796,097.55Ends July 31, 2026
75N93023F00001THE PURPOSE OF THIS TASK ORDER IS TO (A) ACQUIRING, PROCURING AND/OR MANUFACTURING MATERIALS REQUIRED FOR THE GENERATION OF A SCALABLE IN VITRO TRANSCRIPTION (IVT) REACTION, THE PURIFICATION OF THE TRANSCRIBED MRNA, PROCUREMENT/SYNTHESIS OF LIPID RAWDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$6,769,527Ends March 28, 2027
HHSN272201800003CIGF::OT::IGF NONHUMAN PRIMATE CORE VIROLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENTDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$6,148,488.27Ends December 14, 2024
75N93024F00001FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNADepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$5,885,384Ends August 27, 2028
75N94026F00001NICHD: R&D: INNOVATIVE TRIAL DESIGNS AND LABS 2.0: NON-SEVERABLEDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$5,699,498Ends June 28, 2030
75N93025C00006NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENTDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$5,120,519Ends March 29, 2027
140D0422P0227THIS ACQUISITION IS FOR COMMERCIAL OPERATION AND MAINTENANCE SUPPORT SERVICES FOR THE NATIONAL DATA ARCHIVE ON CHILD ABUSE AND NEGLECT (NDACAN) DATABASE. THE ACF IS THE AGENCY WITHIN HHS THAT IS RESPONSIBLE FOR FEDERAL PROGRAMS THAT PROMOTE THE ECONODepartment of the InteriorDepartmental OfficesDURHAM, NC-04$5,011,416.82Ends September 29, 2026
75N94025F00002NICHD: R&D: BPCA PEDIATRIC DRUG DEVELOPMENT CLINICAL TRIAL INFRASTRUCTURE: SEVERABLEDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$4,996,765.70Ends September 19, 2027
75N94025F00001NICHD: R&D: BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) PEDIATRIC TRIALS NETWORK (PTN): CORE FUNCTION ACTIVITIES - THE CONTRACTOR SHALL ESTABLISH AND MAINTAIN CENTRALIZED TEAMS OF EXPERTS WHO WILL DEVELOP PROTOCOLS AND INFORMED CONSENT FORMS ANDDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$4,790,048Ends June 3, 2027
75N93024C00074INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERYDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$4,602,385Ends September 29, 2027
75N94021F00003PHARMACEUTICALS (PK) AND SAFETY OF COMMONLY USED DRUGS IN LACTATING WOMEN AND BREASTFED INFANTS (CUDDLE 2.0) NETWORKDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$3,938,833.11Ends June 30, 2026
75N93024C00005PROMOTING T CELL RECOVERY AFTER RADIATION INJURY WITH LONG-ACTING INTERLEUKIN 7Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$3,499,087Ends February 28, 2027
75N93026C00005VIROLOGY QUALITY ASSURANCE (VQA)Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$3,408,692Ends June 20, 2027
75N93022F00001RESEARCH AND DEVELOPMENT PRODUCT STORAGE AND SHIPPINGDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$2,889,750Ends November 30, 2026
75N94021F00001BPCA PHARMACOEPIDEMIOLOGY (REAL WORLD DATA) STUDIESDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$2,394,451.92Ends May 31, 2026
75N93019F001311500006I DUKE UNIVERSITY; TO 18-0006.B1.0115--06 BASE AWARD; BIOD CAN 8470038 $55,158Department of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$2,360,364.60Ends July 31, 2025
36C24623P1586BRAIN TISSUE PROCESSING WITH DUKE UNIVERSITYDepartment of Veterans AffairsDURHAM, NC-04$2,328,225.57Ends September 12, 2027
75D30123F000022023 CLINICAL IMMUNIZATION SAFETY ASSESSMENT (CISA) BASE IDIQDepartment of Health and Human ServicesCenters for Disease Control and PreventionDURHAM, NC-04$2,171,300Ends May 31, 2027
W912HQ22C0057RC20-3054 FY21 SERDP FUNDS, $100,000.00Department of DefenseDepartment of the ArmyDURHAM, NC-04$1,999,772Ends June 19, 2027
75N93025C00002VIROLOGY CORE LABORATORYDepartment of Health and Human ServicesNational Institutes of HealthDURHAM, NC-04$1,876,865Ends December 14, 2026
75D30126F00004CISA HOME LAIV STUDY- LEAD SITE, EO 14398Department of Health and Human ServicesCenters for Disease Control and PreventionDURHAM, NC-04$1,869,870Ends September 27, 2029
75F40123C00209A STUDY IN MEDICARE ADVANTAGE FOR REAL WORLD EVIDENCE IN CARDIOVASCULAR DISEASEDepartment of Health and Human ServicesFood and Drug AdministrationSILVER SPRING, MD-08$1,567,108Ends June 28, 2027
75D30124F00003CISA RSV INFANTS STUDY (LEAD SITE)Department of Health and Human ServicesCenters for Disease Control and PreventionDURHAM, NC-04$1,532,777.65Ends September 26, 2027
75F40126C00112EO14398 - BROAD AGENCY ANNOUNCEMENT (BAA) FY26C1IP3 - ADVANCED RESEARCH AND DEVELOPMENT OF REGULATORY SCIENCE - CORE CLINICAL OUTCOME ASSESSMENT GRANT PROGRAMDepartment of Health and Human ServicesFood and Drug AdministrationDURHAM, NC-04$1,456,427Ends September 29, 2028
75F40120C00179BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUPDepartment of Health and Human ServicesFood and Drug AdministrationDURHAM, NC-04$1,439,896.36Ends June 30, 2024
7571MN26C00048NATIONAL DATA ARCHIVE ON CHILD ABUSE AND NEGLECT (NDACAN) OPERATIONS AND MAINTENANCE (O&M) SERVICES FOR ACF/CB THIS IS A DOI CONTRACT #140D0422P0227, THAT IS TRANSFERRED TO HHS/ASFR/OMAS.Department of Health and Human ServicesOffice of the Assistant Secretary for Financial ResourcesDURHAM, NC-04$1,395,988.27Ends September 29, 2027
75F40126C00181FIRM FIXED PRICE AWARD TOWARDS ML-POWERED, EFFICIENT AND ROBUST INFERENCE OF AVERAGE AND INDIVIDUAL TREATMENT EFFECTS FOR NOVEL CLINICAL TRIALS IN RARE DISEASES CONTRACTING OFFICER REPRESENTATIVE: DEBORAH ELLIOTT TELEPHONE: (240) 397-3022 DEBODepartment of Health and Human ServicesFood and Drug AdministrationSILVER SPRING, MD-08$1,256,810Ends September 29, 2030

Subcontracts it reported

A prime contractor reports the subcontracts it gives under an award (first-tier subawards). These are the largest it reported under its three largest awards, from every year of each award.

Under award 75N93019C00050

Subcontracts reported under award 75N93019C00050
SubcontractorWhat it is for, as reportedAmountDate
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THEANTIGEN DEVELOPMENT WILL BE DIVIDED INTO 2 PARTS. THE FIRST WILL DEVELOP UNIVERSAL VACCINE IMMUNOGENS. THIS INCLUDES THE OPTIMIZATION OF EACH IMMUNOGEN MRNA FOR PEAK TRANSLATION AND IMMUNOGENICITY AND LACK OF INNATE IMMUNE ACTIVATION. NEXT, MRNA€Ͽ½LNP DELIVERY ROUTES WILL BE EXPLORED TO DEVELOP$1,512,029
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THEANTIGEN DEVELOPMENT WILL BE DIVIDED INTO 2 PARTS. THE FIRST WILL DEVELOP UNIVERSAL VACCINE IMMUNOGENS. THIS INCLUDES THE OPTIMIZATION OF EACH IMMUNOGEN MRNA FOR PEAK TRANSLATION AND IMMUNOGENICITY AND LACK OF INNATE IMMUNE ACTIVATION. NEXT, MRNA€Ͽ½LNP DELIVERY ROUTES WILL BE EXPLORED TO DEVELOP$1,499,639
CHILDREN'S HOSPITAL CORPORATION, THETHE IMMUNOGEN DESIGN AND IMMUNE-RESPONSE EVALUATION DISCOVERY GROUP, LED BY STEPHEN C. HARRISON (BOSTON CHILDREN'S HOSPITAL, HARVARD MEDICAL SCHOOL; HHMI) AND AARON G. SCHMIDT (RAGON INSTITUTE OF HARVARD, MIT AND MASSACHUSETTS GENERAL HOSPITAL; HARVARD MEDICAL SCHOOL), WILL BUILD ON STRUCTURAL STUDI$424,927
CHILDREN'S HOSPITAL CORPORATION, THETHE IMMUNOGEN DESIGN AND IMMUNE-RESPONSE EVALUATION DISCOVERY GROUP, LED BY STEPHEN C. HARRISON (BOSTON CHILDREN'S HOSPITAL, HARVARD MEDICAL SCHOOL; HHMI) AND AARON G. SCHMIDT (RAGON INSTITUTE OF HARVARD, MIT AND MASSACHUSETTS GENERAL HOSPITAL; HARVARD MEDICAL SCHOOL), WILL BUILD ON STRUCTURAL STUDI$424,927
THE GENERAL HOSPITAL CORPORATIONDR. AARON G. SCHMIDT AT MASSACHUSETTS GENERAL HOSPITAL WILL BE A PARTICIPANT IN THIS DUKE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER (CIVIC) AS ONE OF THE INFLUENZA ANTIGEN DISCOVERY TEAMS. DR. SCHMIDT AND HIS TEAM WILL DESIGN AND SELECT HEMAGGLUTININ-BASED IMMUNOGENS THAT WILL BE TRANSFERRED$424,585
THE GENERAL HOSPITAL CORPORATIONDR. AARON G. SCHMIDT AT MASSACHUSETTS GENERAL HOSPITAL WILL BE A PARTICIPANT IN THIS DUKE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER (CIVIC) AS ONE OF THE INFLUENZA ANTIGEN DISCOVERY TEAMS. DR. SCHMIDT AND HIS TEAM WILL DESIGN AND SELECT HEMAGGLUTININ-BASED IMMUNOGENS THAT WILL BE TRANSFERRED$424,585
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THECIVICS A OPTION 22A PRECLINICAL TESTING OF 20 HA MRNA-LNP VACCINE$384,749
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THEOPTION 23E €€Œ THE HENSLEY LABORATORY WILL DEVELOP MRNA VACCINES EXPRESSING MULTIPLE H3N2 AND H1N1 ANTIGENS, SPECIFICALLY, MULTIVALENT H3 VACCINES EXPRESSING HAS FROM 3C2.A AND 3C.3 LINEAGES AND MULTIVALENT H1 VACCINES EXPRESSING HAS FROM PRE-2009 H1N1 STRAINS AND CONTEMPORARY H1N1 STRAINS. THE$384,749
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONTHIS WORK WILL ADVANCE THE HA€Ͽ½ELS PLATFORM AS A POTENTIAL SUPRA€Ͽ½SEASONAL OR PAN€Ͽ½SEROTYPE VACCINE.$384,749
NAJIT TECHNOLOGIES, INC.THE OVERALL GOAL IS TO USE A STRUCTURE-BASED APPROACH TO DEVELOP NEW AND IMPROVED FLU VACCINES BY UTILIZING THE NOVEL HYDROVAX‎¢ VACCINE PLATFORM.$384,430

More subcontracts are reported under this award; the 10 largest are listed.

Under award HHSN272201700061C

Subcontracts reported under award HHSN272201700061C
SubcontractorWhat it is for, as reportedAmountDate
VITALANTINITATE CONTACT, SECURE PARTICIPATION AGREEMENTS AND SERVE AS THE PRIMARY STUDY CONTRACT FOR 6 TARGETED INTERNAL COLLABORATORS A YEAR$223,458
GEORGE WASHINGTON UNIVERSITY (THE)EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY$183,889
GEORGE WASHINGTON UNIVERSITY (THE)PROVIDE A STABILIZED FRAMEWORK FOR EQAPOL SCIENTISTS TO ANALYZE HIV-1 DATA. HIVE TOOLS WILL BE ADAPTED AND ANY NEW PUBLICLY AVAILABLE TOOLS NEEDED FOR ANALYSIS WILL BE INTEGRATED INTO HIVE.$96,102

Lobbying reports and campaign receipts that name this vendor

A name is matched only when it is the same name under the exact-name rule: letters and numbers alike, "&" read as "and", a leading "the" and one closing legal form (Inc, LLC, Corp, Corporation, Co, LP, LLP) set aside. A near name is never a match. Each match says which name matched.

Lobbying reports that name DUKE UNIVERSITY

How it matched: vendor name, exact name: the name in the lobbying report as client.

Lobbying reports
RegistrantClientAmount for the whole quarterQuarterFiledReport
DLA PIPER LLP (US)DUKE UNIVERSITY$80,000reported as incomeThird quarter of 2026Open the report
DUKE UNIVERSITYDUKE UNIVERSITY$201,000reported as expensesThird quarter of 2026Open the report

FEC receipts that name DUKE UNIVERSITY as the employer

How it matched: vendor name, exact name, as the employer of itemized receipts from individuals (FEC).

Only the 25 largest itemized receipts of each committee are saved, so this counts those receipts and no others. An employer is the contributor's own answer on the form.

Suggest a tool

Suggest a tool

A person reads each idea before it appears. Links are not accepted. Do not include personal information.

See all ideas and vote